ArticleCirculation reports2021
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes.
Open access · diamondAbstract read
In one paragraph
Article in Circulation reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 7 pooled it
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 7 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Sodium-glucose Cotransporter 2 Inhibitors Association with Risk of Heart Failure Hospitalization in Preserved and Mildly Reduced Ejection Fraction, Regardless of Diabetes Mellitus: A Systematic Review and Meta-Analysis.Current cardiology reviews · 2026Pooled it
- Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs.Frontiers in endocrinology · 2025Pooled it
- Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis.Age and ageing · 2024Pooled it
- Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.Frontiers in cardiovascular medicine · 2024Pooled it
- Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2023Pooled it
- Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in patients with heart failure: a systematic review and meta-analysis.Cardiovascular diabetology · 2022Pooled it
- Effect of Sodium-Glucose Cotransporter 2 Inhibitors for Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.Frontiers in cardiovascular medicine · 2022Pooled it
- Review
- Pericoronary adipose tissue: potential for pathological diagnosis and therapeutic applications.Cardiovascular intervention and therapeutics · 2025Review
- The landscape of novel antidiabetic drugs in diabetic HFpEF: relevant mechanisms and clinical implications.Cardiovascular diabetology · 2025Review
- Review
- Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape.Heart failure reviews · 2024Review
- Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus.Pharmaceutics · 2023Review
- Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2023Article
- Scientific evidence of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction: an umbrella review of systematic reviews and meta-analyses.Frontiers in cardiovascular medicine · 2023Review
- Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2023Review
- SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier.Reviews in cardiovascular medicine · 2023Review
- Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.International journal of cardiology. Heart & vasculature · 2022Article
- The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 8 institutions in 2 countries.
Tomoya UedaCardiovascular Medicine, Nara Medical University Kashihara Japan.
Shu KasamaInstitute for Clinical and Translational Science, Nara Medical University Hospital Kashihara Japan.
Masahiro YamamotoDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan.
Tomoya NakanoDepartment of Cardiovascular Medicine, Yamato Takada Municipal Hospital Yamatotakada Japan.
Kazuhiro UeshimaDepartment of Cardiovascular Medicine, Yamato Takada Municipal Hospital Yamatotakada Japan.
Yoshinobu MorikawaDepartment of Cardiovascular Medicine, Minami-Nara General Medical Center Nara Japan.
Hiroyuki KawataDepartment of Cardiovascular Medicine, Nara Prefecture General Medical Center Nara Japan.
Akiomi YoshihisaDepartment of Cardiovascular Medicine, Fukushima Medical University Fukushima Japan.
Masafumi NakayamaNakayama Cardiovascular Clinic Kumamoto Japan.
Sei KomatsuCardiovascular Center, Osaka Gyoumeikan Hospital Osaka Japan.
Tsunenari SoedaCardiovascular Medicine, Nara Medical University Kashihara Japan.
Makoto WatanabeCardiovascular Medicine, Nara Medical University Kashihara Japan.
Rika KawakamiCardiovascular Medicine, Nara Medical University Kashihara Japan.
Yasushi OkadaIkuyaku, Integrated Value Development, Mitsubishi Tanabe Pharma Corporation Osaka Japan.
Hiroyuki TanakaIkuyaku, Integrated Value Development, Mitsubishi Tanabe Pharma Corporation Osaka Japan.
Yutaka SusutaIkuyaku, Integrated Value Development, Mitsubishi Tanabe Pharma Corporation Osaka Japan.
Masato KasaharaInstitute for Clinical and Translational Science, Nara Medical University Hospital Kashihara Japan.
Kenichi TsujitaDepartment of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan.
Yasuchika TakeishiDepartment of Cardiovascular Medicine, Fukushima Medical University Fukushima Japan.
Yoshihiko SaitoCardiovascular Medicine, Nara Medical University Kashihara Japan.
CANONICAL Study Group
Nara Medical University Hospital · JPMitsubishi Tanabe Pharma CorporationFukushima Medical University · JPKumamoto University · JPNational Archives and Records Administration · USYamato Municipal Hospital · JPMinamiaoyama Eye Clinic · JPOsaka Ekisaikai Hospital · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
B-type natriuretic peptideElderlyHeart failure with preserved ejection fractionSodium-glucose cotransporter 2 inhibitorsType 2 diabetes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.